The essential result of the present study is that inhibiting the Notch signaling pathway and the CXCR4/CXCL12 axis are central to MASLD progression, improving macrophage polarization, inflammation, and fibrosis. Here, CXCL12 is linked to metabolic dysfunction-associated steatotic liver disease.